These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9792152)

  • 1. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.
    Mead GM; Russell M; Clark P; Harland SJ; Harper PG; Cowan R; Roberts JT; Uscinska BM; Griffiths GO; Parmar MK
    Br J Cancer; 1998 Oct; 78(8):1067-75. PubMed ID: 9792152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract.
    Griffiths GO; Cowan RA; Grigor KM; Uscinska BM; Sydes M; Russell M
    PLoS One; 2019; 14(1):e0210785. PubMed ID: 30650143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
    Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract--a preliminary report.
    Lee MH; Chen MT; Chen KK; Lin AT; Lee YH; Lee LM; Chang YM; Chang LS; Liu JM; Hsieh RK
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S81-4. PubMed ID: 1394825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.
    Harker WG; Meyers FJ; Freiha FS; Palmer JM; Shortliffe LD; Hannigan JF; McWhirter KM; Torti FM
    J Clin Oncol; 1985 Nov; 3(11):1463-70. PubMed ID: 4056840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
    Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
    Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
    Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
    J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
    Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
    ; ; ; ; ; ; ; ; Griffiths G; Hall R; Sylvester R; Raghavan D; Parmar MK
    J Clin Oncol; 2011 Jun; 29(16):2171-7. PubMed ID: 21502557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium.
    Miller RS; Freiha FS; Reese JH; Ozen H; Torti FM
    J Urol; 1993 Jul; 150(1):65-9. PubMed ID: 8510277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
    Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR
    J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMV front-line chemotherapy in transitional bladder carcinoma.
    Paz-Ares L; Lianes P; Díaz-Puente M; Rivera F; Passas J; Costas P; Mendiola C; Cortés-Funes H
    Ann Oncol; 1993 Feb; 4(2):147-50. PubMed ID: 8448083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
    Freiha F; Reese J; Torti FM
    J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial combination chemotherapy with cisplatin, methotrexate and vinblastine in locally advanced transitional cell carcinoma--response rate and pitfalls. MRC Subgroup in Advanced Bladder Cancer (on behalf of the MRC Urological Working Party).
    Fosså SD; Harland SJ; Kaye SB; Raghavan D; Russell JM; Parmar MK; Uscinska BM; Wood R
    Br J Urol; 1992 Aug; 70(2):161-8. PubMed ID: 1393439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
    Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study.
    Meyers FJ; Palmer JM; Freiha FS; Harker EG; Shortliffe LD; Hannigan J; McWhirter K; Torti FM
    J Urol; 1985 Dec; 134(6):1118-21. PubMed ID: 3903223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.